# Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

> **NCT04065438** · NA · RECRUITING · sponsor: **Kaneka Medical America LLC** · enrollment: 35 (estimated)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DEVICE:** LIPOSORBER® LA-15

## Key facts

- **NCT ID:** NCT04065438
- **Lead sponsor:** Kaneka Medical America LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065438, "Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04065438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*